Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: Yahoo! Finance
Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22 At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therapy 93% of subjects had prior CD19 CAR-T Low-dose IL-2 cohort to be included in; Full Phase 1 dataset expected in Q4 2026 Partnerships Servier (through Allogene): Pivotal randomized Phase 2 ALPHA3 trial with cema-cel in 1L consolidation in LBCL: interim futility analysis evaluating MRD clearance and early safety results planned for April 2026 AstraZeneca: Activities progressing under the Joint Research and Collaboration Agreement Cash, cash equivalents and fixed-term deposits of $211 million as of December 31, 2025 provides
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Cellectis Q4 2025 Earnings Preview [Seeking Alpha]Seeking Alpha
- Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 [Yahoo! Finance]Yahoo! Finance
- Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026GlobeNewswire
- Cellectis (NASDAQ:CLLS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $7.00 price target on the stock.MarketBeat
CLLS
Sec Filings
- 3/20/26 - Form 20-F
- 3/20/26 - Form 6-K
- 3/12/26 - Form 6-K
- CLLS's page on the SEC website